Company restores some access to multiple sclerosis drug after pressure from neurologists

Source: BMJ Area: News Genzyme has restored some access to alemtuzumab that it had previously withdrawn. Genzyme withdrew off-label use of alemtuzumab last year for patients with multiple sclerosis, which caused a large amount of unrest amongst neurologists.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news